Logo image of TOI

ONCOLOGY INSTITUTE INC/THE (TOI) Stock Fundamental Analysis

NASDAQ:TOI - Nasdaq - US68236X1000 - Common Stock - Currency: USD

3.5  -0.15 (-4.11%)

After market: 3.5767 +0.08 (+2.19%)

Fundamental Rating

1

Taking everything into account, TOI scores 1 out of 10 in our fundamental rating. TOI was compared to 103 industry peers in the Health Care Providers & Services industry. TOI may be in some trouble as it scores bad on both profitability and health. TOI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TOI has reported negative net income.
TOI had a negative operating cash flow in the past year.
In the past 5 years TOI reported 4 times negative net income.
TOI had negative operating cash flow in 4 of the past 5 years.
TOI Yearly Net Income VS EBIT VS OCF VS FCFTOI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -32.20%, TOI is doing worse than 89.32% of the companies in the same industry.
Looking at the Return On Equity, with a value of -1041.68%, TOI is doing worse than 85.44% of the companies in the same industry.
Industry RankSector Rank
ROA -32.2%
ROE -1041.68%
ROIC N/A
ROA(3y)-21.03%
ROA(5y)-18.04%
ROE(3y)-531.94%
ROE(5y)-331.43%
ROIC(3y)N/A
ROIC(5y)N/A
TOI Yearly ROA, ROE, ROICTOI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

TOI's Gross Margin of 14.70% is on the low side compared to the rest of the industry. TOI is outperformed by 67.96% of its industry peers.
In the last couple of years the Gross Margin of TOI has declined.
The Profit Margin and Operating Margin are not available for TOI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 14.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.94%
GM growth 5Y-6.53%
TOI Yearly Profit, Operating, Gross MarginsTOI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20

More info and screens

2

2. Health

2.1 Basic Checks

TOI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TOI has more shares outstanding
TOI has more shares outstanding than it did 5 years ago.
TOI has a worse debt/assets ratio than last year.
TOI Yearly Shares OutstandingTOI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
TOI Yearly Total Debt VS Total AssetsTOI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of 0.97, we must say that TOI is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of TOI (0.97) is worse than 70.87% of its industry peers.
TOI has a Debt/Equity ratio of 14.58. This is a high value indicating a heavy dependency on external financing.
TOI's Debt to Equity ratio of 14.58 is on the low side compared to the rest of the industry. TOI is outperformed by 85.44% of its industry peers.
Industry RankSector Rank
Debt/Equity 14.58
Debt/FCF N/A
Altman-Z 0.97
ROIC/WACCN/A
WACC8.16%
TOI Yearly LT Debt VS Equity VS FCFTOI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 1.79 indicates that TOI should not have too much problems paying its short term obligations.
TOI's Current ratio of 1.79 is fine compared to the rest of the industry. TOI outperforms 65.05% of its industry peers.
TOI has a Quick Ratio of 1.59. This is a normal value and indicates that TOI is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.59, TOI is in line with its industry, outperforming 58.25% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.79
Quick Ratio 1.59
TOI Yearly Current Assets VS Current LiabilitesTOI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.60% over the past year.
TOI shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.64%.
TOI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.41% yearly.
EPS 1Y (TTM)13.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.73%
Revenue 1Y (TTM)17.64%
Revenue growth 3Y24.68%
Revenue growth 5Y20.41%
Sales Q2Q%10.29%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y61.9%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year16.43%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TOI Yearly Revenue VS EstimatesTOI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M
TOI Yearly EPS VS EstimatesTOI Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TOI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TOI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TOI Price Earnings VS Forward Price EarningsTOI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TOI Per share dataTOI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TOI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ONCOLOGY INSTITUTE INC/THE

NASDAQ:TOI (7/18/2025, 8:16:12 PM)

After market: 3.5767 +0.08 (+2.19%)

3.5

-0.15 (-4.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-12 2025-08-12
Inst Owners35.14%
Inst Owner Change0%
Ins Owners4.1%
Ins Owner Change9.58%
Market Cap312.31M
Analysts84
Price Target6.63 (89.43%)
Short Float %7.15%
Short Ratio2.91
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.14%
PT rev (3m)225%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.77
P/FCF N/A
P/OCF N/A
P/B 61.61
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.7
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.18
OCFYN/A
SpS4.52
BVpS0.06
TBVpS-0.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.2%
ROE -1041.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 14.7%
FCFM N/A
ROA(3y)-21.03%
ROA(5y)-18.04%
ROE(3y)-531.94%
ROE(5y)-331.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.94%
GM growth 5Y-6.53%
F-Score2
Asset Turnover2.46
Health
Industry RankSector Rank
Debt/Equity 14.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 53.28%
Cap/Sales 0.87%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.79
Quick Ratio 1.59
Altman-Z 0.97
F-Score2
WACC8.16%
ROIC/WACCN/A
Cap/Depr(3y)87.81%
Cap/Depr(5y)78.43%
Cap/Sales(3y)1.52%
Cap/Sales(5y)1.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.73%
EPS Next Y61.9%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)17.64%
Revenue growth 3Y24.68%
Revenue growth 5Y20.41%
Sales Q2Q%10.29%
Revenue Next Year16.43%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y16.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year107.61%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y71.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y74.03%
OCF growth 3YN/A
OCF growth 5YN/A